Ashley Swartz, NP
Primary Care · Bedford, PANPI 1528601739
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 293 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 33.9% of the total. 2025 is the largest year on record at $2,355, more than ten times the $209 reported in 2021. Among primary care clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 293 payments — averaging $15.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$581
- Otsuka America Pharmaceutical, Inc.$363
- Alkermes, Inc.$311
- Teva Pharmaceuticals USA, Inc.$301
- Johnson & Johnson$291
- plus $1K from 16 others
What the payments were for
- Food & beverage$4,53198%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 127 | $1,570 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $581 |
| Otsuka America Pharmaceutical, Inc. | 23 | $363 |
| Alkermes, Inc. | 18 | $311 |
| Teva Pharmaceuticals USA, Inc. | 13 | $301 |
| Johnson & Johnson | 15 | $291 |
| Lundbeck LLC | 14 | $244 |
| Neurocrine Biosciences, Inc. | 8 | $164 |
| Axsome Therapeutics, Inc. | 6 | $145 |
| Indivior Inc. | 7 | $140 |
| Novo Nordisk | 6 | $122 |
| E.r. Squibb & Sons, L.L.C. | 3 | $82 |
| Supernus Pharmaceuticals, Inc. | 4 | $75 |
| Gilead | 4 | $54 |
| Amgen | 2 | $38 |
| Merck | 2 | $36 |
| Corium, LLC | 2 | $27 |
| Seqirus USA Inc | 1 | $19 |
| Braeburn Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Boston Scientific | 1 | $16 |
How this compares
$4,631 in reported general payments places this provider in the 90th percentile of 300 primary care providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 30 | $42,834 |
| LatudaLurasidone Hcl | 22 | $28,989 |
| RexultiBrexpiprazole | 20 | $27,650 |
| MounjaroTirzepatide | 15 | $16,207 |
| JardianceEmpagliflozin | 11 | $6,837 |
| Lurasidone Hcl | 11 | $4,978 |
| Clozapine | 36 | $4,949 |
| Aripiprazole | 62 | $4,078 |
| Quetiapine Fumarate | 189 | $3,237 |
| LoxapineLoxapine Succinate | 61 | $2,642 |
| Paliperidone ErPaliperidone | 23 | $2,124 |
| Chlorpromazine Hcl | 11 | $2,102 |
| Bupropion XlBupropion Hcl | 108 | $1,821 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 18 | $1,784 |
| Gabapentin | 98 | $1,711 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $1,570 | $42,83430 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $363 | $27,65020 claims |
| Lilly USA, LLCMounjaro, Olanzapine | $17 | $16,87041 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $301 | $2,64261 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 300 primary care providers in Pennsylvania.
Other primary care in Bedford
- Kersten ReiderMount Penn$121K
- Teresa GiamboyPhiladelphia$21K
- Nicole IlgenfritzBethel Park$18K
- Galyna VorokhibPhiladelphia$12K
- Melissa BeansWarrington$12K
- Mollie McGuireJohnstown$11K
- Andrea MauriceNew Cumberland$11K
- Kendell SoglieroSmithfield$9K
- Minjung RegerDoylestown$9K
- Mackenzie HouserMedia$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.